Gold prices edge higher; Russia-Ukraine, Jackson Hole symposium in spotlight
LONDON - Oxford Biomedica PLC (LSE:OXB) announced Friday that its Non-Executive Director and Chair, Dr. Roch Doliveux, has purchased 67,000 ordinary shares in the company at a price of £4.4975 per share.
The transaction, which took place on the London Stock Exchange, amounts to a total investment of £301,332.50. Following this purchase, Dr. Doliveux now holds 438,805 shares, representing 0.413% of the company.
Oxford Biomedica, which describes itself as a cell and gene therapy CDMO (Contract Development and Manufacturing Organization), made the disclosure in accordance with EU Market Abuse Regulation requirements.
The notification details that the purchase involved ordinary shares of 50 pence each with the ISIN code GB00BDFBVT43.
The information was released in a regulatory news service announcement by the company based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.